Stockreport

Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders

Zevra Therapeutics, Inc.  (ZVRA) 
PDF Highlights 54.8% Total Stockholder Return Under Refreshed Board and Management Team Zevra Continues Growth Trajectory into a Global Commercial Rare Disease Company with [Read more]